The merger is a reverse merger that will effectively take Serapha public. The key risk is the pending Beam Therapeutics trade secret litigation, which could materially impact the combined company's ability to develop SERP-01. Monitor the December 3, 2026 stockholder vote and any developments in the Beam litigation.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Oct 30 $2.44entry
- T+1 · 2d ago −2.46%α −2.76% · $2.38
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Boundless Bio, Inc. filed an amended S-4 registration statement for its proposed merger with Serapha Bio, Inc. Under the merger agreement, Serapha will become a wholly owned subsidiary of Boundless Bio, with Boundless Bio renamed Serapha Bio, Inc. Existing Boundless Bio stockholders are expected to own approximately 3.8% of the combined company on a fully-diluted basis, while former Serapha securityholders will own approximately 96.2%. Boundless Bio stockholders will receive a pre-closing cash dividend of approximately $44 million to $48 million. The filing also includes employment offer letters for Serapha's post-merger executive team.
Key Facts
- Boundless Bio and Serapha entered into a merger agreement dated June 22, 2026, as amended August 28, 2026.
- Existing Boundless Bio stockholders expected to own ~3.8% of the combined company; former Serapha securityholders ~96.2%.
- Boundless Bio stockholders to receive a pre-closing special cash dividend of approximately $44 million to $48 million.
- Boundless Bio has ceased all clinical development of its legacy product candidates.
- Combined company will focus on SERP-01, an in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).
- Serapha completed a Series A financing of approximately $138 million and a pre-closing financing of approximately $92 million.
- Serapha is a defendant in a trade secret misappropriation lawsuit filed by Beam Therapeutics Inc. on September 25, 2026.
- Post-merger management includes Kenneth Mills (CEO), Daphne Karydas (President/CFO), Weston Miller (CMO), Nina Hunter (CDO), and Shiva Fritsch (CCAO).
- Boundless Bio special meeting of stockholders scheduled for December 3, 2026.
- Combined company expected to trade on Nasdaq under symbol AATD.
Financial Impact
Boundless Bio stockholders to receive pre-closing dividend of approximately $44M-$48M. Existing Boundless Bio holders diluted to ~3.8% ownership of combined entity. Serapha raised ~$138M in Series A and ~$92M in pre-closing financing.
Risk Factors
- Pending Beam Therapeutics trade secret misappropriation lawsuit could prevent or delay development of SERP-01.
- Nasdaq listing condition may be waived, risking trading on OTC markets.
- Boundless Bio stockholders face massive dilution to ~3.8% ownership.
- Combined company will need additional capital beyond the ~$230M raised pre-merger.
- SERP-01 is an early-stage, unproven base editing therapy with limited clinical data.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-442255 |
| Document: d108148dex1027.htm | 0001193125-26-442255 |
| Document: d108148dex1026.htm | 0001193125-26-442255 |
| Document: d108148dex1025.htm | 0001193125-26-442255 |
| Document: d108148dexfilingfees.htm | 0001193125-26-442255 |
| Document: d108148dex51.htm | 0001193125-26-442255 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | EFFECT | $2.38 | awaiting T+5 | awaiting T+5 | $2.44 (+2.52%) |
Oct 30, 2026 4d ago | S-4/A | $2.44 | awaiting T+5 | awaiting T+5 | $2.44 (+0.00%) |
Oct 26, 2026 8d ago | 425 | $2.41 $2.38 | ▼ −1.24% | ▲ +0.74% | $2.44 (+1.24%) |
Oct 26, 2026 9d ago | 425 | $2.41 $2.47 | ▲ +2.49% | ▲ +3.75% | $2.44 (+1.24%) |
Oct 8, 2026 26d ago | S-4 | $2.53 $2.34 | ▲ +7.51% | ▲ +5.54% | $2.44 (+3.56%) |
Aug 28, 2026 9w ago | 425 / 8-K | $2.81 $2.86 | ▲ +1.78% | ▲ +1.92% | $2.44 (−13.17%) |
Jul 8, 2026 16w ago | Insider Cluster | $2.51 $2.49 | ▼ −0.80% | ▼ −0.67% | $2.44 (−2.79%) |
Jul 6, 2026 17w ago | Insider Cluster | $2.50 $2.46 | ▼ −1.60% | ▼ −2.15% | $2.44 (−2.40%) |
Jun 29, 2026 18w ago | 3 | $2.50 $2.50 | · 0.00% | ▼ −0.60% | $2.44 (−2.40%) |
May 8, 2026 25w ago | 8-K | $1.44 $1.55 | ▲ +7.64% | ▲ +6.18% | $2.44 (+69.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers